Study guide
10.5 Cancer-Associated Thrombosis & Anticoagulation
Advanced Oncology Certified Nurse Practitioner AOCNP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 About the AOCNP Exam 1.2 How to Use This AOCNP Study Guide
2 Chapter 2: Cancer Continuum - Risk, Prevention & Screening
2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities 2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery 2.3 Cancer Screening & Early Detection Guidelines 2.4 Screening for Subsequent & Second Primary Malignancies 2.5 Hereditary Cancer Syndromes & Genetic Counseling
3 Chapter 3: Cancer Continuum - Assessment, Diagnosis & Staging
3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation 3.2 Pathology Interpretation, Histology & Tumor Grading 3.3 Cancer Staging Systems (TNM) & Prognostication Models 3.4 Performance Status, Frailty & Geriatric Assessment
4 Chapter 4: Cancer Continuum - Planning, Coordination & Survivorship
4.1 Established Guidelines for Care & Categories of Evidence 4.2 Individualized Treatment Planning & Molecular Tumor Boards 4.3 Reproductive Planning & Fertility Preservation 4.4 Patient Navigation & Interprofessional Care Coordination 4.5 Survivorship Care Planning & Late Effects Management 4.6 Post-Treatment Surveillance for Cancer Recurrence
5 Chapter 5: Cancer Treatment - Antineoplastic Pharmacology & Chemotherapy
5.1 Antineoplastic Principles, Dosing & Dose Adjustments 5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management 5.3 Safe Administration, Handling & Infusion Toxicities 5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring
6 Chapter 6: Cancer Treatment - Targeted, Immuno & Hormonal Therapies
6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs 6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy 6.3 Endocrine & Hormonal Therapies in Oncology
7 Chapter 7: Cancer Treatment - Radiation, Surgery, Regional & Multimodal Therapy
7.1 Radiation Oncology Principles & Toxicity Management 7.2 Surgical Oncology, Perioperative Care & Reconstruction 7.3 Regional & Localized Therapy Administration 7.4 Multimodal Therapy & Treatment Sequencing 7.5 Complementary, Alternative & Integrative Therapies
8 Chapter 8: Cancer Treatment - Transplantation, Clinical Trials & Response
8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy 8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)
9 Chapter 9: Supportive Care - Pain & Controlled Substance Safety
9.1 Cancer Pain Assessment & Comprehensive Analgesic Management 9.2 Controlled Substance Safety & Opioid Stewardship 9.3 Nonpharmacologic & Integrative Symptom Interventions
10 Chapter 10: Supportive Care - Symptom & Comorbidity Management
10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms 10.2 Gastrointestinal Symptom Management (CINV, Mucositis, Diarrhea) 10.3 Hematologic & Neurologic Toxicity Management 10.4 Dermatologic, Metabolic & Fatigue Management 10.5 Cancer-Associated Thrombosis & Anticoagulation 10.6 Comorbid Conditions & Their Interaction With Cancer Treatment 10.7 Palliative Care, Hospice & End-of-Life Management
11 Chapter 11: Oncologic Emergencies
11.1 Superior Vena Cava Syndrome & Structural Emergencies 11.2 Spinal Cord Compression & Neurologic Emergencies 11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy 11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation 11.5 Cardiopulmonary & Airway Emergencies 11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH
12 Chapter 12: Psychosocial Issues
12.1 Psychosocial Assessment & Distress Screening in Oncology 12.2 Risk Factors & At-Risk Oncology Populations 12.3 Psychosocial & Emotional Sequelae of Disease and Treatment 12.4 Psychiatric & Psychosocial Comorbidities in Cancer Care 12.5 Caregiver Burden, Support & Community Resources
13 Chapter 13: Professional Practice & Roles of the APRN
13.1 APRN Scope of Practice, Prescriptive Authority & Standards of Care 13.2 Bioethics, Informed Consent & Quality Improvement in Oncology 13.3 Cultural Competence, Implicit Bias & Equitable Oncology Care 13.4 Accreditation Standards & Outcomes of APRN Practice 13.5 Competency Evaluation, Peer Review & Peer Education
10.5 Cancer-Associated Thrombosis & Anticoagulation
Key Takeaways Explain This Topic AI
Venous thromboembolism is the second-leading cause of death in patients with cancer and occurs at roughly four to seven times the rate of the general population.
The Khorana score stratifies chemotherapy-associated venous thromboembolism risk using tumor site, prechemotherapy platelet count, hemoglobin or growth factor use, leukocyte count, and body mass index, with a score of 2 or higher marking intermediate-to-high risk.
Direct oral anticoagulants such as apixaban, rivaroxaban, and edoxaban are guideline-endorsed for cancer-associated thrombosis but carry increased major bleeding risk in luminal gastrointestinal and genitourinary malignancies, where low-molecular-weight heparin is preferred.
Anticoagulation is generally continued for at least 6 months and for as long as the cancer is active or treatment continues.
For platelet counts between 25,000 and 50,000/µL, dose-reduced anticoagulation with platelet transfusion support is used, and full-dose anticoagulation is generally held below 25,000/µL.
Last updated: August 2026
10.5 Cancer-Associated Thrombosis & Anticoagulation
Blueprint focus: ONCC Domain II.L and II.N — pharmacologic management of a treatment- and disease-related complication, and the interrelationship between the malignancy, its treatment, and a comorbid condition. Venous thromboembolism is common, lethal, and heavily protocolized, which makes it reliable exam material.
Scale of the Problem
Venous thromboembolism (VTE) is the second-leading cause of death in patients with cancer, after the cancer itself. Patients with malignancy have roughly four to seven times the VTE rate of the general population, and a VTE diagnosis independently predicts worse survival. Recurrence on anticoagulation is also far more common than in patients without cancer.
Virchow's triad in malignancy:
Hypercoagulability — tumor cells express tissue factor and cancer procoagulant, release procoagulant microparticles, and generate inflammatory cytokines. Adenocarcinomas, particularly mucin-producing tumors, are the strongest drivers.
Stasis — immobility from fatigue, hospitalization, surgery, and direct vascular compression by tumor or bulky adenopathy.
Endothelial injury — central venous catheters, surgery, and endothelial-toxic drugs.
Highest-risk tumor types: pancreas, stomach, brain (particularly glioblastoma), lung, ovary, kidney, and hematologic malignancies including multiple myeloma treated with immunomodulatory agents.
Treatment-related contributors: cisplatin, immunomodulatory drugs (lenalidomide, thalidomide, pomalidomide) especially combined with dexamethasone, anti-angiogenic agents such as bevacizumab, tamoxifen, erythropoiesis-stimulating agents, high-dose corticosteroids, central venous catheters, and major abdominal or pelvic surgery.
Risk Assessment: The Khorana Score
- Variable Points
- Very high-risk tumor site — stomach, pancreas 2
- High-risk tumor site — lung, lymphoma, gynecologic, bladder, testicular 1
- Prechemotherapy platelet count ≥ 350,000/µL 1
- Hemoglobin < 10 g/dL or use of an erythropoiesis-stimulating agent 1
- Prechemotherapy leukocyte count > 11,000/µL 1
- Body mass index ≥ 35 kg/m² 1
Interpretation: 0 = low risk; 1 to 2 = intermediate; 3 or more = high risk. ASCO recommends considering thromboprophylaxis for ambulatory patients with a Khorana score of 2 or higher starting chemotherapy, after discussing bleeding risk.
Prophylaxis
Setting Recommendation
Hospitalized medical patients with active cancer Pharmacologic prophylaxis unless actively bleeding or at high bleeding risk
Major cancer surgery Pharmacologic prophylaxis started preoperatively or early postoperatively; extended prophylaxis for 4 weeks after major open abdominal or pelvic surgery
Ambulatory patients on chemotherapy Not routine; consider apixaban, rivaroxaban, or low-molecular-weight heparin when the Khorana score is 2 or higher and bleeding risk is acceptable
Multiple myeloma on an immunomodulatory drug plus dexamethasone Prophylaxis is required — aspirin for low-risk patients, low-molecular-weight heparin or a direct oral anticoagulant for higher-risk patients
Central venous catheters Routine prophylaxis is not recommended
Primary brain tumors Prophylaxis is used; a brain tumor is not by itself an absolute contraindication, although intracranial hemorrhage risk must be weighed
- Treatment of Established Cancer-Associated Thrombosis
- Agent selection
Agent class Position Cautions
Low-molecular-weight heparin (enoxaparin, dalteparin) Long-standing standard; preferred with luminal gastrointestinal or genitourinary tumors, significant drug interactions, impaired absorption, vomiting, or severe thrombocytopenia Renal dose adjustment; injection burden
Direct oral anticoagulants (apixaban, rivaroxaban, edoxaban) Guideline-endorsed and non-inferior for recurrence; oral convenience improves adherence Increased major gastrointestinal and genitourinary bleeding , especially with intact luminal tumors; avoid with strong CYP3A4 and P-glycoprotein interactions; avoid in severe renal impairment
Unfractionated heparin Used when rapid reversibility is needed, or with severe renal failure Requires monitoring; heparin-induced thrombocytopenia risk
Warfarin Inferior in cancer; erratic control from nutrition, vomiting, drug interactions, and hepatic metastases Reserve for when the alternatives are contraindicated
Duration
Anticoagulate for at least 6 months , and continue as long as the cancer is active, metastatic, or being treated . Reassess at intervals rather than stopping automatically at 6 months.
Recurrence on anticoagulation
Recurrent VTE while anticoagulated is common. Confirm adherence and absorption first, then escalate — typically by increasing the low-molecular-weight heparin dose by 20% to 25%, or converting a direct oral anticoagulant to low-molecular-weight heparin. Inferior vena cava filters are not first-line ; they are reserved for absolute contraindications to anticoagulation, and should be retrieved once anticoagulation becomes possible.
Special Situations
Catheter-related thrombosis. Anticoagulate therapeutically. The catheter may stay in place if it is functional, correctly positioned, non-infected, and still needed. Remove it if it is non-functional, malpositioned, infected, or if symptoms persist despite anticoagulation — and when removal is necessary, give several days of anticoagulation first where feasible.
Thrombocytopenia. This is the most frequently tested nuance.
- Platelet count Approach
- > 50,000/µL Full-dose anticoagulation
25,000 to 50,000/µL Dose-reduced anticoagulation, with platelet transfusion support to maintain the count above 40,000 to 50,000/µL during the acute period
< 25,000/µL Generally hold full-dose anticoagulation; consider a retrievable IVC filter if the thrombus is recent and life-threatening
Incidental pulmonary embolism discovered on a staging scan is treated the same as a symptomatic event, because outcomes are comparable.
Brain metastases are not an absolute contraindication; melanoma, renal cell carcinoma, and choriocarcinoma metastases carry the highest hemorrhage risk and warrant the most caution.
Neuraxial procedures — lumbar puncture, intrathecal chemotherapy, epidural placement — require agent-specific hold intervals to avoid spinal hematoma. Coordinate timing explicitly rather than assuming.
Patient Education
Teach the symptoms of deep vein thrombosis (unilateral limb swelling, pain, warmth, erythema) and of pulmonary embolism (sudden dyspnea, pleuritic chest pain, hemoptysis, syncope, tachycardia) as call-immediately events.
Teach injection technique, site rotation, and safe sharps disposal for low-molecular-weight heparin.
Review bleeding precautions: soft toothbrush, electric razor, fall prevention, and avoidance of NSAIDs unless specifically approved.
Emphasize that anticoagulation must not be self-discontinued because of minor bruising, and that any planned procedure requires advance coordination.
Encourage mobility and hydration, and address the cost and injection burden that commonly drive silent non-adherence.